Bio-Techne (MIL:1TECH) Cyclically Adjusted Revenue per Share: €7.16 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1TECH Bio-Techne Corp MIL:1TECH
61 GF Score
Price €62.06
GF Value €63.27
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Bio-Techne Cyclically Adjusted Revenue per Share?

Bio-Techne MIL:1TECH 61 Cyclically Adjusted Revenue per Share is €7.16 as of Mar. 2026. GuruFocus rates MIL:1TECH with a GF Score™ of 61/100 and a GF Value™ of €63.27 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bio-Techne's adjusted revenue per share for the three months ended in Mar. 2026 was €1.711. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €7.16 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Bio-Techne's average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bio-Techne was 15.80% per year. The lowest was 8.60% per year. And the median was 11.35% per year.

As of today (2026-07-15), Bio-Techne's current stock price is €62.06. Bio-Techne's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €7.16. Bio-Techne's Cyclically Adjusted PS Ratio of today is 8.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Techne was 34.02. The lowest was 6.37. And the median was 14.03.


Bio-Techne  (MIL:1TECH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bio-Techne's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=62.06/7.16
=8.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Techne was 34.02. The lowest was 6.37. And the median was 14.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bio-Techne Cyclically Adjusted Revenue per Share Related Terms


Bio-Techne Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bio-Techne's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne Cyclically Adjusted Revenue per Share Chart

Bio-Techne Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 5.31

Bio-Techne Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5.31 5.29 6.17 7.16

MIL:1TECH vs ARWR, CYTK, KRYS: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Cyclically Adjusted PS Ratio falls into.


MIL:1TECH
61GF Score
Bio-Techne Corp MIL:1TECH
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Techne Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Techne's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.711/330.2130*330.2130
=1.711

Current CPI (Mar. 2026) = 330.2130.

Bio-Techne Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.802 241.018 1.099
201609 0.776 241.428 1.061
201612 0.834 241.432 1.141
201703 0.898 243.801 1.216
201706 0.928 244.955 1.251
201709 0.804 246.819 1.076
201712 0.859 246.524 1.151
201803 0.872 249.554 1.154
201806 1.004 251.989 1.316
201809 0.900 252.439 1.177
201812 0.990 251.233 1.301
201903 1.052 254.202 1.367
201906 1.084 256.143 1.397
201909 1.060 256.759 1.363
201912 1.052 256.974 1.352
202003 1.117 258.115 1.429
202006 0.987 257.797 1.264
202009 1.083 260.280 1.374
202012 1.145 260.474 1.452
202103 1.257 264.877 1.567
202106 1.310 271.696 1.592
202109 1.331 274.310 1.602
202112 1.446 278.802 1.713
202203 1.609 287.504 1.848
202206 1.667 296.311 1.858
202209 1.679 296.808 1.868
202212 1.585 296.797 1.763
202303 1.700 301.836 1.860
202306 1.716 305.109 1.857
202309 1.602 307.789 1.719
202312 1.562 306.746 1.681
202403 1.739 312.332 1.839
202406 1.770 314.175 1.860
202409 1.619 315.301 1.696
202412 1.766 315.605 1.848
202503 1.840 319.799 1.900
202506 1.752 322.561 1.794
202509 1.561 324.800 1.587
202512 1.609 324.054 1.640
202603 1.711 330.213 1.711

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €7.16 mean?
Bio-Techne (MIL:1TECH) has a Cyclically Adjusted Revenue per Share of €7.16 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Techne and its competitors.
Is Bio-Techne's Cyclically Adjusted Revenue per Share too high?
Bio-Techne's current Cyclically Adjusted Revenue per Share is €7.16. Overall, Bio-Techne has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Cyclically Adjusted Revenue per Share compare to ARWR and CYTK?
Bio-Techne's Cyclically Adjusted Revenue per Share of €7.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bio-Techne and its competitors. Bio-Techne's current Cyclically Adjusted Revenue per Share is €7.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (MIL:1TECH) is currently considered Fairly Valued. The stock's GF Value™ is €63.27, compared to a current price of €62.06 — trading 1.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €7.16. Bio-Techne's overall GF Score™ is 61/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bio-Techne (MIL:1TECH), the current Cyclically Adjusted Revenue per Share is €7.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Techne (MIL:1TECH) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued. The current stock price of €62.06 is trading 1.9% below its estimated GF Value™ of €63.27. GuruFocus considers Bio-Techne to be Fairly Valued.

Key valuation signals for MIL:1TECH:

  • Cyclically Adjusted Revenue per Share: €7.16
  • GF Value™: €63.27 vs. price of €62.06 (1.9% below fair value)
  • GF Score™: 61/100 with 8 warning signs

No single metric tells the full story. See the MIL:1TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bio-Techne Business Description

Address 614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
61GF Score

Get the complete analysis for MIL:1TECH

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€62.06
Price
€63.27
GF Value